23andMe Investor Presentation Deck

1. 2. A Research and Development Pipeline Covering Multiple Therapeutic Areas Immuno-oncology GSK'608¹ (CD96) EARLY-STAGE THERAPEUTIC AREAS (multiple programs in each area) Immuno-oncology Immunology 23ME'610 (CD200R1) Cardiovascular/ Metabolic Neurology Discovery Preclinical Phase 1 50+ programs² GSK is solely responsible for the development of GSK6097608 (GSK'608) in later-stage clinical trials. Subject to its successful commercialization, 23andMe is eligible to earn tiered worldwide royalties up to the low double digits. The 50+ programs in the combined therapeutic areas include 100% owned and royalty interest targets as well as those in collaborations. The majority of the programs are in collaboration with GSK. Note: As of March 31, 2022 Phase 2 GSK 23andMe Copyright © 2023 23andMe, Inc. 23andMe 35

View entire presentation